Dr. Peritt is a cellular immunologist by training with substantial industry experience in biologics and cell therapy. He was formerly Chief Technology Officer at Sigilon Therapeutics, a Flagship Pioneering company, until soon after they went public in late 2020.
Prior to this he was Program Lead for Cell and Gene therapy at Pfizer, Head of Biosimilars Biology and scientific lead for strategic investment in cell therapy for Hospira. For a decade, David also led research efforts at several divisions of Johnson & Johnson including Centocor and Therakos as well as experiences at ImClone Systems, USDA, Walter Reed Army Medical Center and the Sharrett Cancer Institute.
Dr. Peritt received his Ph.D. and post-doctoral training in immunology from the University of Pennsylvania and the Wistar Institute. He also serves as an adjunct professor, Vice Chairman MBP Advisory Board at Northwestern University McCormick School of Engineering. He advises for several cell and gene therapy companies.